{"article_id": "CRL_q1_2021.txt", "article": ["our robust first quarter financial performance , highlighted by 13 % organic revenue growth and 170 basis points of year - over - year operating margin improvement demonstrates the strength of the biopharmaceutical market environment and the power of our unique portfolio , both of which we believe are as strong as they have ever been .", "organic revenue was about 10 % for a second consecutive quarter , even after normalizing for last year 's covid - 19 impact .", "quarterly revenue surpassed $ 800 million for the first time and an $ 824.6 million for the first quarter of 2021 represented a 16.6 % increase over last year .", "organic revenue growth of 13 % was driven by double - digit growth across all three segments .", "the year - over - year comparison to last year 's covid - related revenue impact , which primarily affected the rms segment , contributed approximately 140 basis points to the revenue growth rate this quarter .", "the operating margin was 20.7 % , an increase of 170 basis points year - over - year .", "we expect the same factors will drive margin improvement for the year and believe the operating margin will approach 21 % , above our prior target .", "earnings per share were $ 2.53 in the first quarter , an increase of 37.5 % from $ 1.84 in the first quarter of last year .", "we now expect organic revenue growth in a range of 12 % to 14 % , a 300 basis point increase from our prior range .", "non-gaap earnings per share are expected to be $ 9.75 to $ 10 , which represents 20 % to 23 % year - over - year growth and an increase of $ 0.75 at the midpoint from our prior outlook .", "revenue was $ 501.2 million in the first quarter , an 11.6 % increase on an organic basis over the first quarter 2020 driven by broad - based demand for both discovery and safety assessment .", "the dsa operating margin increased by 180 basis points to 23.8 % in the first quarter .", "leverage from the robust dsa revenue growth was the primary driver of margin improvement , and we expect this trend will continue to propel the dsa margin into the mid-20 % range for the year .", "rms revenue was $ 176.9 million , an increase of 14.8 % on an organic basis over the first quarter of 2020 .", "approximately 620 basis points of the increase was attributable to the comparison to last year 's covid - related revenue impact from client site closures and disruption .", "in the first quarter , the rms operating margin increased 570 basis points to 28.7 % .", "first , last year 's 23 % margin was depressed by the onset of covid - related client disruptions and the resulting impact on the research model order activity .", "revenue for the manufacturing segment was $ 146.5 million , a 15.6 % increase on an organic basis over the first quarter of last year .", "the manufacturing segment 's first quarter operating margin was stable at 35.5 % .", "this is consistent with the historical trend in the first quarter and in line with our revised expectations in 2021 for a mid-30 % operating margin when factoring in the cognate acquisition .", "microbial solutions growth rate rebounded above the 10 % level in the first quarter , reflecting strong demand for our endosafe endotoxin testing systems , cartridges and core reagents for all geographic regions .", "we delivered strong revenue growth , well above the 10 % level on an organic basis and significant operating margin expansion of 170 basis points , which drove earnings - per - share growth of 37.5 % to $ 2.53 .", "we now expect to deliver reported revenue growth of 19 % to 21 % and organic revenue growth in a range of 12 % to 14 % for the full year .", "given the robust top line performance , we expect to drive meaningful operating margin improvement this year with the full year margin approaching 21 % .", "this is expected to drive better - than - expected earnings per share in a range of $ 9.25 to $ 10 , which represents year - over - year growth above 20 % .", "including the acquisition of cognate , manufacturing 's reported revenue growth rate is expected to be in the high - 30 % range .", "with regard to operating margin , rms will continue to be a primary contributor to the overall improvement for the year , with the segment margin meaningfully above 25 % .", "we also expect the dsa segment operating margin to increase over the prior year into the mid-20 % range .", "when factoring in cognite , the manufacturing segment 's operating margin is expected to be in the mid-30 % range this year or moderately below its 2020 level .", "unallocated corporate costs was slightly higher than our expectations , totaling 6.2 % of total revenue or $ 51.2 million in the first quarter compared to 5.6 % of revenue in the first quarter of last year .", "despite the higher expenses in the first quarter , we continue to expect unallocated corporate costs to be in the mid -5 % range as a percentage of revenue for the full year .", "the first quarter tax rate was 14.5 % , a 20 basis point increase year - over - year and consistent with our outlook in february , which calls for a tax rate in the mid-teens due to the gating of the excess tax benefit from stock - based compensation .", "we continue to expect our full year tax rate will be in the low - 20 % range on a non-gaap basis , which is unchanged from our outlook provided in february .", "total adjusted net interest expense for the first quarter was $ 17.1 million , which was essentially flat sequentially and a decrease of nearly $ 2 million year - over - year due to lower average debt levels , which resulted in interest rate savings based on our leverage ratio .", "at the end of the first quarter , we had $ 2.2 billion of outstanding debt , representing a gross leverage ratio of 2.3 times and a net leverage ratio of 1.9 times .", "in march , we issued $ 1 billion of senior notes to further optimize our capital structure and take advantage of the attractive interest rate environment .", "the proceeds of this bond offering we used to redeem a previously issued higher - rate $ 500 million bond to pay down the existing term loan and a portion of the revolving credit facility and to finance a portion of the cognate acquisition .", "in april , we also amended our existing credit agreement to establish a new revolver with borrowing capacity of up to $ 3 billion .", "the net result of these actions will reduce our average interest rate on debt by approximately 50 basis points to 2.65 % .", "on a pro forma basis , including the cognate and retrogenix acquisitions , our gross leverage ratio was just under three times , and we had total debt outstanding of slightly below $ 3 billion .", "for the year , the higher debt balances due primarily to cognate acquisition will be partially offset by the lower average interest rate from these refinancing activities , which is expected to result in total adjusted net interest expense of $ 83 million to $ 86 million .", "free cash flow was $ 142.2 million in the first quarter , a significant increase compared to $ 42.9 million last year .", "capital expenditures were $ 28 million in the first quarter compared to $ 25.7 million last year .", "looking ahead , we are increasing our capex guidance for 2021 by $ 40 million to approximately $ 220 million .", "even with the additional capital , we expect capex will remain below 7 % of our total revenue this year , which is consistent with the target that we provided at our last investor day in 2019 .", "for the full year , we are updating our free cash flow guidance to the upper end of the prior range and now expect free cash flow of approximately $ 435 million for the full year .", "we now expect second quarter reported revenue growth at or near the 30 % level , including the contribution of cognate .", "on an organic basis , we expect second quarter growth rate to be at or near 20 % .", "this reflects the prior year comparison to the covid - related revenue impact , which will contribute approximately 700 basis points to the second quarter revenue growth .", "our expectation for non-gaap earnings per share is a growth rate of more than 50 % year - over - year ."], "summary_gold": "compname reports q1 non gaap earnings per share of $ 2.53 .<q>q1 non -gaap earnings per share $ 2.53 .<q>q1 revenue rose 16.6 percent to $ 824.6 million .<q>updates 2021 guidance .<q>sees 2021 reported revenue growth of 19 % - 21 % .<q>sees 2021 organic revenue growth of 12 % - 14 % .<q>2021 gaap earnings per share estimate of $ 5.95 - $ 6.20.2021 non-gaap earnings per share estimate of $ 9.75 - $ 10.00 .", "summary_pred": "the first quarter tax rate was 14.5 % , a 20 basis point increase year - over - year and consistent with our outlook in february , which calls for a tax rate in the mid-teens due to the gating of the excess tax benefit from stock - based compensation .<q>we continue to expect our full year tax rate will be in the low - 20 % range on a non-gaap basis , which is unchanged from our outlook provided in february .<q>in march , we issued $ 1 billion of senior notes to further optimize our capital structure and take advantage of the attractive interest rate environment .<q>we delivered strong revenue growth , well above the 10 % level on an organic basis and significant operating margin expansion of 170 basis points , which drove earnings - per - share growth of 37.5 % to $ 2.53 .<q>the manufacturing segment 's first quarter operating margin was stable at 35.5 % .<q>looking ahead , we are increasing our capex guidance for 2021 by $ 40 million to approximately $ 220 million .<q>on a pro forma basis , including the cognate and retrogenix acquisitions , our gross leverage ratio was just under three times , and we had total debt outstanding of slightly below $ 3 billion .<q>given the robust top line performance , we expect to drive meaningful operating margin improvement this year with the full year margin approaching 21 % .<q>the net result of these actions will reduce our average interest rate on debt by approximately 50 basis points to 2.65 % .<q>first , last year 's 23 % margin was depressed by the onset of covid - related client disruptions and the resulting impact on the research model order activity .<q>the proceeds of this bond offering we used to redeem a previously issued higher - rate $ 500 million bond to pay down the existing term loan and a portion of the revolving credit facility and to finance a portion of the cognate acquisition .<q>organic revenue growth of 13 % was driven by double - digit growth across all three segments .<q>we expect the same factors will drive margin improvement for the year and believe the operating margin will approach 21 % , above our prior target .<q>we also expect the dsa segment operating margin to increase over the prior year into the mid-20 % range .", "len_article": 50, "len_summary_gold": 7, "len_summary_pred": 14, "len_sent_scores": 50}